WithdrawnPhase 4

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

Stopped: Lack of interest

0Started 2022-12-01

Plain-language summary

AGN-190584 has gone through many clinical trials showing its safety and effectiveness in individuals from 40-55 years of age. There has been no published data on the use of this product in individuals corrected with contact lenses for distance vision. There are many other applications AGN-190584 could be used for and further studies will show the effectiveness for each.

Who can participate

Age range40 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects from age 40-55 * Prescription range: -4.00 - +1.00 * Correctable to 20/25 or better for distance * Adapted single use contact lens patients * Subjects able to understand the consent agreement and willing to participate Exclusion Criteria: * Non-contact lens wearer * Previous use of AGN-190584 * Out of age range * Out of prescription range * Any corneal abnormality * Any eye pathology * Iritis * Know allergy to pilocarpine

What they're measuring

The primary endpoint will be changes from baseline in letters read at near without loss of distance acuity (defined as loss of 5 or more letters)

Timeframe: 30 days

Trial details

NCT IDNCT05624320

SponsorGordon Schanzlin New Vision

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-30

View on ClinicalTrials.gov More Presbyopia trials